Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncolys BioPharma Inc.

Latest From Oncolys BioPharma Inc.

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.

Deals M & A

US venture Acucela looks east for $125m IPO

Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline.


Oncolys shares still ahead after $46m IPO

The Japanese venture Oncolys BioPharma has floated on the Mothers high-tech market of the Tokyo Stock Exchange, raising around JPY4.7bn ($46m) to develop its pipeline of drugs and diagnostics for cancer and serious infections.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Oncolys BioPharma Inc.
  • Senior Management
  • Yasuo Urata, Pres. & CEO
    Yasunari Kashihara, VP, Bus. Dev.
  • Contact Info
  • Oncolys BioPharma Inc.
    Phone: (81) 3-5472-1578
    4-1-28 Toranomon
    Tokyo, 105-0001